Imagenetix, Inc.

Imagenetix, Inc. develops, formulates, and markets proprietary and natural based nutritional supplements, and over-the-counter topical creams and skin care products. Its primary product is Celadrin, a product formulation for joint health. The company also licenses its intellectual property to third parties. Imagenetix, Inc. markets its products through various channels of distribution, including direct and mass marketing companies, nutritional newsletters, and medical and nutritional oriented professionals; medical newsletters; and direct response radio and television. The company was founded in 1996 and is based in San Diego, California.

Imagenetix, Inc. trades as IAGX on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Imagenetix, Inc. can be compared against peers such as BZAM Ltd., CanaQuest Medical Corp., Ventura Cannabis & Wellness Corporation, GlobeImmune, Inc., New Leaf Ventures Inc, Neurobiological Technologies, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $2,842, beta of -406.06, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

IAGX currently shows total debt of N/A and beta of -406.06. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.imagenetix.net

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.